Nolato NOLA B
This picture changes. Follow Nolato free — email when the signal or risk changes + a Sunday weekly brief.
Follow Nolato freeEmail when the signal or risk changes · Sunday weekly brief
No card · No time limit on free tier · Upgrade when you need more
Full analysis: 6 Apr 2026
Latest news check: 18 Jul 2026
General analysis — not personal advice.
NEUTRAL
6/10
Confidence
Hold off on adding until the company demonstrates a steadier margin trend and clearer pricing impact; an existing position can be maintained if you accept higher near-term earnings risk.
Post-Q2, uncertainty around margin recovery and pricing pass-through is higher, warranting a reassessment until there is clearer evidence that cost inflation can be passed on and margins normalize.
Market sentiment
2/10
↓
Trend: Declining
Sentiment has weakened materially after Q2 as investors focus on how quickly cost inflation can be offset through pricing and whether margins stabilize over the next quarters.
Risk assessment
6/10
Dilution:
Low
Positive cash flow; no announced equity raise
Jurisdiction:
Low
Mainly Sweden/EU/US; limited high-risk exposure
Execution:
Medium
New factory ramps require validation and quality control
Recent changes
- Q2 showed FX-adjusted revenue growth but pressured profitability from higher raw material/oil costs and delayed price pass-through, triggering a sharp negative share reaction.
The full analysis is open. Follow the company free for the full change history — and email next time the picture changes.
Show all changes (5) — follow the company freeAbout the company
Nolato is a contract manufacturer developing and producing polymer-based components and systems (plastics, silicone, TPE) for medical/drug delivery and industrial customers. The company is profitable and in a mature phase, focusing on margin improvement and capacity expansion. A key growth driver is scaling pen/autoinjector components linked to diabetes and obesity therapies.
Sector:
Polymer-based contract manufacturing (medtech and industrial)
Type:
Industrial
Next report
29 Oct 2026
Q3
Catalysts
29 Oct 2026
Q3 2026 interim report
High
29 Oct 2026
Q3 / nine-month report 2026
High
31 Dec 2026
End of former CEO advisory period
Low
Horizon:
Bull case
If pricing actions flow through in H2 2026 while volume growth continues, margins could recover and valuation could normalize from depressed levels.
Bear case
If raw material costs keep rising or pricing pass-through remains delayed, margin pressure may persist and drive further negative estimate revisions.
Signal rationale (informational)
Post-Q2, uncertainty around margin recovery and pricing pass-through is higher, warranting a reassessment until there is clearer evidence that cost inflation can be passed on and margins normalize.
Recent news
- Since 19 June, Nolato has divested its Romania operations (annual sales just over SEK 60m, below-group profitability; completion expected in Q4 2026). On 17 July, the Q2 report was released: sales increased (currency-adjusted) but profitability was pressured by higher raw material/oil costs and a lag in passing price increases to customers, triggering a sharp negative share price reaction. In connection with the report, Anders Björklund assumed the role of CEO and President.
Price & valuation
Last close
SEK 50.50
1 week
+2.3 %
3 months
+0.4 %
12 months
-9.1 %
From 52w high
-18.0 %
From 52w low
+11.4 %
Exchange
Stockholm
Type
Industrials
Sector
Polymer-based contract manufacturing (medtech and industrial)
This picture changes. Follow Nolato free — email when the signal or risk changes + a Sunday weekly brief.
Follow 3 companies freeEmail when the signal or risk changes · Sunday weekly brief
No card · No time limit on free tier · Upgrade when you need more
Firelda provides general information and analysis, not personal investment advice. Content does not consider your financial situation or goals. Investments can rise and fall in value. Always do your own research.